- Amgen has announced a $650 million expansion of its biologics manufacturing facility in Juncos, Puerto Rico, expected to create nearly 750 jobs including construction and skilled manufacturing roles.
- The investment will support increased drug production and integrate advanced technologies, building on more than $40 billion Amgen has invested in US manufacturing and R&D since 2017.
Amgen has announced a $650 million expansion of its US manufacturing network, creating nearly 750 new jobs at its biologics manufacturing facility in Juncos, Puerto Rico. The investment will support increased drug production and integrate advanced technologies throughout the operations process, with new roles including construction positions and highly skilled manufacturing jobs.
The biotechnology company’s chairman and chief executive officer Robert A. Bradway said the expansion underscores the firm’s commitment to US biomanufacturing and strengthening global supply chain resilience. The investment in contract manufacturing capacity aims to better serve patients whilst creating jobs that reinforce America’s biotechnology leadership.
The announcement represents Amgen’s continued commitment to US innovation and operations, reflected in more than $40 billion invested in manufacturing and research since the passage of the Tax Cuts and Jobs Act in 2017. The company stated that pro-growth tax policies, extended by the One Big Beautiful Bill Act of 2025, facilitate its ability to invest domestically in science and manufacturing.
Puerto Rico Governor Jenniffer González Colón described the expansion as strengthening US supply chain security through reshoring whilst positioning Puerto Rico as a biopharmaceutical hub. The territory has more than 60 years of expertise in the sector, according to Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce.
The investment follows recent Amgen expansions including a $600 million science centre in California, a $900 million manufacturing expansion in Ohio, and a $1 billion expansion in North Carolina. The CDMO investment in Juncos will add to the company’s existing biologics manufacturing capabilities in the region.
